This article will briefly discuss prevalence studies and the pathophysiology of NAFLD and focus on current discussions related to the specific lesions in the pathology of NASH, including the ...

In the medical field, terminology not only guides clinical understanding and patient communication but also impacts research, ...

Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

Drawing on years of experience studying non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD), SMC has created the world’s first preclinical model with a type 2 diabetic ...

Although all patients with NAFLD need aggressive management of cardiovascular risk factors, it is only patients with NASH who need treatment targeted at the liver disease. None of the currently ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

At the moment, Madrigal Pharmaceuticals seems to be in the lead to bring a NASH drug to market, after its daily oral drug resmetirom met primary and secondary objectives in a phase 3 NAFLD trial ...

Since symptoms don’t appear until the condition worsens, the only way to detect fatty liver early is through blood tests (LFT ...

Fatty liver disease, or hepatic steatosis, occurs when excess fat accumulates in liver cells. Commonly associated with ...

It is the progressive form of non-alcoholic fatty liver disease (NAFLD). NASH can lead to cirrhosis and liver cancer. The gut–liver axis is of crucial importance in health and disease.

Madrigal Pharmaceuticals (MDGL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yasmeen ...